Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Citi
UBS
Moodys
Cantor Fitzgerald
Daiichi Sankyo
Federal Trade Commission
Boehringer Ingelheim
Baxter
Teva
Queensland Health

Generated: October 17, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,083,808

« Back to Dashboard

Which drugs does patent 7,083,808 protect, and when does it expire?


Patent 7,083,808 protects APTENSIO XR and is included in one NDA. There have been four Paragraph IV challenges on Aptensio XR.

This patent has eighteen patent family members in fourteen countries.

Summary for Patent: 7,083,808

Title:Controlled/modified release oral methylphenidate formulations
Abstract: The invention is directed to oral modified/controlled release methylphenidate formulations which provide a rapid initial onset of effect and a prolonged duration of effect. Preferably, the peak concentration is lower than that provided by the reference standard for immediate release methylphenidate formulations, and the duration of effect falls rapidly at the end of the dosing interval so as not to affect the appetite of the patient at dinner nor the patient's sleep thereafter.
Inventor(s): Goldenheim; Paul D. (Wilton, CT), Sackler; Richard S. (Greenwich, CT), Krishnamurthy; Thinnayam N. (Ontario, CA), Darke; Andrew (Ontario, CA), Oshlaci; Benjamin (New York, NY)
Assignee: Euro-Celtique S.A. (Luxembourg, LU)
Application Number:10/741,081
Patent Claim Types:
see list of patent claims
Formulation; Compound; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Rhodes Pharms
APTENSIO XR
methylphenidate hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL205831-001Apr 17, 2015RXYesNo► Subscribe► SubscribeY
Rhodes Pharms
APTENSIO XR
methylphenidate hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL205831-002Apr 17, 2015RXYesNo► Subscribe► SubscribeY
Rhodes Pharms
APTENSIO XR
methylphenidate hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL205831-003Apr 17, 2015RXYesNo► Subscribe► SubscribeY
Rhodes Pharms
APTENSIO XR
methylphenidate hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL205831-004Apr 17, 2015RXYesNo► Subscribe► SubscribeY
Rhodes Pharms
APTENSIO XR
methylphenidate hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL205831-005Apr 17, 2015RXYesNo► Subscribe► SubscribeY
Rhodes Pharms
APTENSIO XR
methylphenidate hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL205831-006Apr 17, 2015RXYesNo► Subscribe► SubscribeY
Rhodes Pharms
APTENSIO XR
methylphenidate hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL205831-007Apr 17, 2015RXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 7,083,808

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,673,367 Controlled/modified release oral methylphenidate formulations► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,083,808

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Portugal1967191► Subscribe
Portugal1140088► Subscribe
Lithuania1967191► Subscribe
Japan5844676► Subscribe
Japan2012184235► Subscribe
Japan5186100► Subscribe
Japan2007119479► Subscribe
Japan4663880► Subscribe
Japan2002532426► Subscribe
Hong Kong1124257► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Novartis
Julphar
Baxter
Boehringer Ingelheim
Mallinckrodt
Federal Trade Commission
Dow
UBS
US Department of Justice
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot